Register Now

Benefit from wide-ranging and multi-disciplinary content including keynote lectures, roundtable discussions, cancer control program and tobacco forum, oral abstracts, and poster presentations.

Early Registration ends November 18, 2022.

#LALCA23
lalca2023.iaslc.org
TABLE OF CONTENTS

WELCOME MESSAGE ............................................................................................................. 5
IASLC & PROGRAM COMMITTEE .......................................................................................... 7
VENUE FLOORPLAN ............................................................................................................. 9
PROGRAM ............................................................................................................................ 11
POSTER SESSIONS ............................................................................................................. 21
EDUCATION AWARDS ........................................................................................................ 29
ABSTRACT AUTHOR INDEX .............................................................................................. 31
INDUSTRY SUPPORTERS & EXHIBITORS ..................................................................... 37
GENERAL INFORMATION .................................................................................................. 39

CONFERENCE SECRETARIAT
International Conference Services Ltd. (ICS)
Suite 710, 1201 West Pender Street, Vancouver, BC, Canada, V6E 2V2
Phone: +1 604 681 2153
www.icsevents.com

GLOBAL OFFICES
Vancouver, Toronto, Texas, London, Barcelona, Vienna, Tokyo, Singapore
Welcome Message
Welcome Message

On behalf of the International Association for the Study of Lung Cancer (IASLC), we are pleased to welcome you to the IASLC 2022 Asia Conference on Lung Cancer (ACLC2022) at Nara Prefectural Convention Center. We are thrilled that you join us again in a face-to-face meeting with virtual elements that will enhance participant’s experience and allow anyone from anywhere to join this unique meeting. Over 400 participants are joining us in beautiful Nara to share information about the frontiers of clinical and basic research, clinical management, and multidisciplinary care.

We would like to extend our gratitude and thanks to all industry supporters and exhibitors for their support of the Asia Conference on Lung Cancer and the IASLC. Without them this Conference would not be possible.

Thank you for joining us in Nara.

We look forward to hosting all of you over the next couple of days.

Best Regards,

Tetsuya Mitsudomi
MD, PhD
Department of Surgery, Division of Thoracic Surgery
Kindai University
Faculty of Medicine

Myung-Ju Ahn
MD, PhD
Professor of Hematology
Samsung Medical Center

James CH Yang
MD, PhD
Superintendent, National Taiwan University Cancer Center
Professor, Graduate Institute of Oncology, National Taiwan University
IASLC & Program Committee
IASLC & Program Committee

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes nearly 6,000 lung cancer specialists in over 100 countries.

IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. IASLC publishes the Journal of Thoracic Oncology, a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.

**The IASLC mission is:**
- To embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies.
- To provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public.
- To use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world.

**Program Committee**

**Advanced / Metastatic NSCLC**
- Caicun Zhou, Chair, China
- Dong Wan Kim, Republic of Korea
- Kazuhiko Nakagawa, Japan
- Daniel Tan, Singapore
- Solange Peters, Switzerland
- Misako Nagasaka, USA
- Jin-Yuan Shih, Taiwan
- Thanyanan Reungwetwattana, Thailand
- Chia-Chi Lin, Taiwan

**Diagnosis, Imaging, and Bronchoscopy**
- Chao-Chi Ho, Chair, Taiwan
- Ho Yun Lee, Republic of Korea
- Shuji Sakai, Japan

**Early Stage NSCLC**
- Young Tae Kim, Chair, Republic of Korea
- Yi-Long Wu, China
- Roy Herbst, USA
- Stephen Liu, USA
- Ichiro Yoshino, Japan
- Hidehito Horinouchi, Japan
- Jing-Shin Chen, Taiwan

**Locally Advanced NSCLC**
- Ross Soo, Chair, Singapore
- Hong-Gyun Wu, Republic of Korea
- Luis Paz-Ares, Spain
- Terufumi Kato, Japan
- Isamu Okamoto, Japan
- Kayoko Ohnishi, Japan
- Sita Laksmsi Andarini, Indonesia

**Palliative and Supportive Care**
- Akira Inoue, Chair, Japan
- David Currow, Australia
- David Hui, USA

**Risk Reduction, Early Detection, Epidemiology and Tobacco Control**
- Pan-Chyr Yang, Chair, Taiwan
- Abhishek Shankar, India

**SCLC, Mesothelioma and Thymoma**
- Jie Wan, Chair, China
- Se Hoon Lee, Republic of Korea
- Yasushi Goto, Japan

**Translational Science, Basic Science, and Pathology**
- Yasushi Yatabe, Chair, Japan
- Teh-Ying Chou, Taiwan
- Chong-Jen Yu, Taiwan
Venue
Floorplan
Venue Floorplan

Nara Prefectural Convention Center - 1F

Nara Prefectural Convention Center - 2F

- Conference Hall A
- Conference Hall B
- Conference Hall C
- Waiting Rooms
- Escalator to 2F
- Elevator to 2F
- Main Entrance
- Washrooms
- Prayer / Mothers Room
- 105
- 106
- 107
- 108
- 102
- 101
- 104
- 103
- Registration
- Breakout Room 204
- Plenary Hall 203
- Exhibition & Posters
- Speaker Preview Center
- Washrooms
- Exit to JW Hotel Nara
- Exit
Program
ACLC 2022 | aclc2022.iaslc.org

Program

THURSDAY | OCTOBER 27, 2022

Registration Desk Opening Hours: 09:30 – 18:00
Speaker Preview Center Opening Hours: 09:30 – 17:00

EC01 - Early Career Workshop
Plenary Hall | Room 203 | 2F

10:00 – 12:00 Chairs: James Chin-Hsin Yang, Taiwan & Karen Kelly, USA
10:00 – 10:02 Welcome and Introduction
10:02 – 10:17 EC01.01: Challenges and/or Opportunities for Early Career Researchers
Derek De-Rui Huang, Taiwan
10:17 - 10:32 EC01.02: How to Improve Acceptance Rate of Manuscript into JTO
Ross Soo, Singapore
10:32 - 10:47 EC01.03: How to Set Up an Investigator Initiated Trial
Keunchil Park, Republic of Korea
10:47 - 11:02 EC01.04: How to Build an Engaging Presentation
Tony Mok, Hong Kong
11:02 - 11:17 EC01.05: How to Build Up Physician Scientists
Hiroyuki Yasuda, Japan
11:17 - 11:32 EC01.06: Benefits of Joining IASLC as a Young Doctor
Karen Kelly, USA
11:32 – 12:00 Q&A Discussion

WTO01 - Women in Thoracic Oncology
Breakout Room | Room 204 | 2F

10:30 – 12:00 Chairs: Myung-Ju Ahn, Republic of Korea & Tetsuya Mitsudomi, Japan
10:30 – 10:32 Welcome and Introduction
10:32 – 10:47 WTO01.01: How to Support Other Women’s Voices in Meetings
Jie Wang, China
10:47 – 11:02 WTO01.02: How to Balance Family Life and Work as Women Doctor
Miyako Satouchi, Japan
11:02 – 11:17 WTO01.03: Experience of Thoracic Surgeon as Women Doctor
Yeol Kim, Republic of Korea
11:17 – 11:32 WTO01.04: How to Be a Good Mentor
Heather Wakelee, USA
11:32-11:47 WTO01.05: Hints for a Better Work Environment
Mio Saga, USA
11:47-12:00 Q&A Discussion

12:00 - 12:30 Networking Lunch
Plenary Hall | Room 203 | 2F
Lunch will be provided

PL01 - Lung Cancer in Asia: Opportunities & Challenges
Plenary Hall | Room 203 | 2F

12:30 – 14:00 Chairs: Myung-Ju Ahn, Republic of Korea & Pan-Chyr Yang, Taiwan
12:30 – 12:32 Welcome and Introduction
12:32 - 12:52 PL01.01: Molecular Epidemiology of Lung Cancer in Asia
Yu-Ju Chen, Taiwan
12:52 - 13:12 PL01.02: Current Status of Clinical Trials of Lung Cancer and How to Improve Drug Accessibility in Asia
Ross Soo, Singapore
13:12 - 13:32 PL01.03: Medical Big Data of NSCLC Based on CDM (Common Data Model)
Akihiko Genma, Japan
Yi-Long Wu, China
13:52 - 14:00 Q&A Discussion

ES01 - The Epidemiology and Lung Cancer Screening Programs in Asia
Plenary Hall | Room 203 | 2F

14:00 – 15:00 Chairs: Sita Andarini, Indonesia & Pan-Chyr Yang, Taiwan
Track: Risk Reduction, Early Detection, Epidemiology and Tobacco Control
14:00 – 14:02 Welcome and Introduction
14:02 - 14:14 ES01.01: Challenges of Lung Cancer Screening in Developing Countries in Asia
Abhishek Shankar, India
14:14 - 14:26 ES01.02: Current Status of Lung Cancer Screening in Japan
Kazuto Ashizawa, Japan
14:26 - 14:38 ES01.03: Lung Cancer Screening Program in Korea
Yeol Kim, Republic of Korea
14:38 - 14:50 ES01.04: Lung Cancer Screening for Non Smokers
Woo-Jin Lee, Republic of Korea
14:50 – 15:00 Q&A Discussion

11: Conquering Thoracic Cancers Worldwide
ES02 - Perioperative Therapy Reloaded: Immunotherapy and Targeted Therapy for Early Stage NSCLC
Breakout Room | Room 204 | 2F
14:00 – 15:00 Chairs: Hidehito Horinouchi, Japan & Pham Cam Phuong, Vietnam

Track: Early Stage NSCLC
14:00 – 14:02 Welcome and Introduction
14:02 - 14:14 ES02.01: Practical Challenges Perioperative Systemic Therapy in Early Stage Lung Cancer (Endocrine, Hypothyroidism, Autoimmune, etc)
Sun Min Lim, Republic of Korea
14:14 – 14:26 ES02.02: How to Decide Neoadjuvant vs. Adjuvant Treatment
Junichi Soh, Japan
14:26 – 14:38 ES02.03: How We Select Patients for Chemo-Immuino Surgery vs. Chemo-Immuino-Radiation
Junko Tanizaki, Japan
14:38 – 14:50 ES02.04: Precision Selection of Patients Using Novel Biomarkers for Perioperative Treatment
Si-Yang Liu, China
14:50 – 15:00 Q&A Discussion

ES04 - Advances in Multi-Modality Treatment of Locally Advanced NSCLC
Breakout Room | Room 204 | 2F
15:45 – 16:45 Chairs: Haruko Daga, Japan & Chee Lee, Australia

Track: Locally Advanced NSCLC
15:45 – 15:47 Welcome and Introduction
15:47 - 15:59 ES04.01: Advances in Radiation Therapy in the Era of Immunotherapy
Changhoon Song, Republic of Korea
15:59 - 16:11 ES04.02: Novel Immunotherapy Approaches Beyond Consolidation Durvalumab
Chee Lee, Australia
16:11 - 16:23 ES04.03: Molecular Targeted Therapy - Is There a Role?
Terufumi Kato, Japan
16:23 - 16:35 ES04.04: Survivorship Issues: Closing the Care Gap
Sita Andarini, Indonesia
16:35 - 16:45 Q&A Discussion

ES03 - New Horizons in Lung Cancer Diagnosis from Imaging
Plenary Hall | Room 203 | 2F
15:45 – 16:45 Chairs: Ho Yun Lee, Republic of Korea, Shuji Sakai, Japan

Track: Diagnosis, Imaging, and Bronchoscopy
15:45 – 15:47 Welcome and Introduction
15:47 - 15:59 ES03.01: Response Evaluation or Complications Related to Immunotherapy
Shuji Sakai, Japan
15:59 - 16:11 ES03.02: Lung MRI for Lung Cancer
Yoshiharu Ohno, Japan
16:11 - 16:23 ES03.03: AI in Lung Cancer
Joon Beom Seo, Republic of Korea
16:23 - 16:35 ES03.04: Imaging Findings for Precision Medicine
Geewon Lee, Republic of Korea
16:35 - 16:45 Q&A Discussion

OA01 – Oral Abstract Session 1
Plenary Hall | Room 203 | 2F
17:00 – 18:00 Chairs: Karen Kelly, USA & Pan-Chyr Yang, Taiwan
17:00 - 17:12 OA01.01: Is Computed Tomographic Screening for Lung Cancer Associated with Lung Cancer Overdiagnosis Among Asian Women?
Hsiu-Hsi Chen, Taiwan
17:12 - 17:24 OA01.02: Operational Management Challenges in Continuing Lung Cancer Screening during COVID-19 Pandemic
Prerna Gautam, India
17:24 - 17:36 OA01.03: Safety of Lung Cancer Surgery in Patients with History of SARS-CoV-2 Infection In the Post-vaccination Era: A Single Center Experience
Somin Im, Republic of Korea
17:36 - 17:48 OA01.04: Biomarker Analysis from a Phase II Alternating Therapy with Osimertinib and Afatinib for EGFR-Mutated NSCLC (WJOG10818L)
Kimio Yonesaka, Japan
17:48 - 18:00 Q&A Discussion

Networking Break
Exhibit Hall | Room 201+202 | 2F
Refreshments will be provided
**Poster Viewing**

Exhibit Hall | Room 201+202 | 2F

*Refreshments will be provided*

18:00 - 19:00  Poster Tour 1 & 2
18:00 - 19:00  Poster Viewing Reception A

For further details, please refer to the Poster Section, pages 24 - 26.

**IS01 – Industry Symposium Sponsored by MSD**

K.K.: Advances in Treatment with Immune Checkpoint Inhibitors for NSCLC  
Breakout Room | Room 204 | 2F

*Refreshments will be provided*

19:00 – 20:00  Chair: Makoto Maemondo, Japan
19:00 – 20:00  Advances in Treatment with Immune Checkpoint Inhibitors for NSCLC  
Masahiro Tsuboi, Japan
FRIDAY | OCTOBER 28, 2022

Registration Desk Opening Hours: 08:00 – 16:00
Speaker Preview Center Opening Hours: 08:00 – 16:00

PL02 – New Horizons of Immunotherapy in Lung Cancer
Plenary Hall | Room 203 | 2F

08:45 – 10:15 Chairs: Karen Kelly, USA & Tetsuya Mitsudomi, Japan
08:45 – 08:47 Welcome and Introduction
08:47 - 08:57 Education Award Presentations
Tetsuya Mitsudomi, Japan
08:57 - 09:12 PL02.01: Revisiting Cancer Vaccine Using Neoantigen
Hirokazu Matsushita, Japan
09:12 - 09:27 PL02.02: CAR T Cell Therapy in Solid Tumors
Koji Tamada, Japan
09:27 - 09:42 PL02.03: Novel Antibodies Including BiTEs
Solange Peters, Switzerland
09:42 - 09:57 PL02.04: New Checkpoints
Chia-Chi (Josh) Lin, Taiwan
09:57 – 10:15 Q&A Discussion

10:15 – 10:45 Networking Break
Exhibit Hall | Room 201+202 | 2F
Refreshments will be provided

ES05 - Immunotherapy
Plenary Hall | Room 203 | 2F

10:45 – 11:45 Chairs: Solange Peters, Switzerland & Nobuyuki Yamamoto, Japan
Track: Advanced/Metastatic NSCLC - Immunotherapy
10:45 – 10:47 Welcome and Introduction
10:47 – 11:00 ES05.01: Personalized Immunotherapy
Myung-Ju Ahn, Republic of Korea
11:00 – 11:13 ES05.02: Immunotherapy in Special Population
Motoko Tachihara, Japan
11:13 – 11:26 ES05.03: Emerging Immunotherapy Combination
Solange Peters, Switzerland

11:26 - 11:39 ES05.04: IPRACTIC - A Proposed Statistical Analysis Pipeline For Blood Based Longitudinal Immunomonitoring For Immunotherapy Clinical Trial
Joe Yeong, Singapore

11:39 - 11:45 Q&A Discussion

ES06 - New Horizons in Lung Cancer Diagnosis: Bronchoscopy for Biopsy and Staging
Breakout Room | Room 204 | 2F

10:45 – 11:45 Chairs: Noriaki Kurimoto, Japan & Chong-Jen Yu, Taiwan
Track: Diagnosis, Imaging, and Bronchoscopy
10:45 – 10:47 Welcome and Introduction
10:47 – 10:59 ES06.01: Transbronchial Cryobiopsy for Peripheral Pulmonary Lesions
Yuji Matsumoto, Japan
10:59 – 11:11 ES06.02: Bronchoscopic Transparenchymal Nodule Access (BTPNA)
Jiayuan Sun, China
11:11 – 11:23 ES06.03: Robotic Bronchoscopy
David I K Fielding, Australia
11:23 – 11:35 ES06.04: Transesophageal Bronchoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-B-FNA)
Hwangbo Bin, Republic of Korea
11:35 – 11:45 Q&A Discussion

IS02 – Industry Symposium Sponsored by MERCK Healthcare KGaA: Decisive Moments in the Treatment of MET exon 14 Skipping NSCLC
Plenary Hall | Room 203 | 2F
Lunch will be provided

12:00 – 13:00 Chair: Terufumi Kato, Japan
12:00 – 12:05 A Moment to Welcome You
Terufumi Kato, Japan
12:05 – 12:15 Take a Moment to Consider Identification and Treatment
Yasushi Goto, Japan
12:15 – 12:25 A Moment of Clarity: Has our VISION for MET exon 14 Skipping Become a Reality?
Nir Peled, Israel
12:25 - 12:40 A Moment to Examine Treatment Outcomes and the VISION Study in Asian Patients
James Yang, Taiwan

12:40 - 12:50 Make Every Moment Matter: Optimising Treatment
Led by Terufumi Kato, Japan

12:50 - 13:00 A Moment to Reflect on MET exon 14 Skipping
Terufumi Kato, Japan

ISO03 – Industry Symposium Sponsored by Physicians’ Education Resource®, LLC: Advancing Precision Care Through Biomarker-Driven Therapy: CEACAM5 as a Therapeutic Target in NSCLC
Breakout Room | Room 204 | 2F
Lunch will be provided

12:00 – 13:00 Chair: Solange Peters, Switzerland
12:00 - 12:05 Welcome, Introductions, Pre-Session Survey
Solange Peters, Switzerland
12:05 - 12:20 CEACAM5: What Is It, and How and Where Is It Expressed
Ross Soo, Singapore
12:20 - 12:30 Testing for CEACAM5: Does Tissue Play A Central Role?
Ming Tsao, Canada
12:30 - 12:45 Clinical Validation of CEACAM5 as a Therapeutic Target
Solange Peters, Switzerland
12:45 - 12:50 Post Session Survey
12:50 - 12:55 Panel Discussion
12:55 - 13:00 Question & Answer Session

OA02 – Oral Abstract Session 2
Plenary Hall | Room 203 | 2F

13:15 - 14:30 Chairs: Yasushi Goto, Japan & Keunchil Park, Republic of Korea
13:15 - 13:27 OA02.01: Differential Diagnosis of Rare Thoracic Tumors Characterized by Gene Rearrangement Using RNA Pan-Cancer Panel
Harumi Nakamura, Japan
13:27 - 13:39 OA02.02: The Association of Tumor Metastatic Score and Overall Survival in Patients with Stage IV Non-small Cell Lung Cancer Bearing Extra-thoracic Metastases
Yen-lin Chen, Taiwan
13:39 - 13:51 OA02.03: AKT Pathway as a Therapeutic Target to Constrain Lineage Plasticity Leading to Histological Transdifferentiation
Alvaro Quintanal-Villalonga, USA
13:51 - 14:03 OA02.04: A Phase Ib Study of AK112, a PD-1/VEGF Bispecific Antibody, in Combination with Etoposide and Carboplatin in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Shun Lu, China

14:03 - 14:15 OA02.05: Fear of Cancer Recurrence and its Predictors among Patients with Non-Small Cell Lung Cancer (NSCLC)
Wonyoung Jung, Republic of Korea

14:15 - 14:27 OA02.06: CRESTONE: Initial Efficacy and Safety of Seribantumab in Solid Tumors Harboring NRG1 Fusions
Misako Nagasaka, USA

14:27 - 14:30 Q&A Discussion

ES07 - Surgery for Early Stage NSCLC: Beyond Lobectomy
Plenary Hall | Room 203 | 2F
Lunch will be provided

14:30 – 15:30 Chairs: Young Tae Kim, Republic of Korea & Ichiro Yoshino, Japan
Track: Early Stage NSCLC

14:30 -14:32 Welcome and Introduction
14:32 - 14:44 ES07.01: Current Evidence of Sublobar Resection for Lung Cancer
Hisashi Saji, Japan
14:44 - 14:56 ES07.02: Sublobar Resections for Early NSCLC - Pulmonary Function Preservation?
Wentao Fang, China
14:56 - 15:08 ES07.03: Oncologic Unmet Needs of Sublobar Resection
Samina Park, Switzerland
15:08 - 15:20 ES07.04: Robotic Surgery for Sublobar Resection
Seong Yong Park, Republic of Korea
15:20 - 15:30 Q&A Discussion

ES08 - SCLC
Breakout Room | Room 204 | 2F

14:30 – 15:30 Chairs: Miyako Satouchi, Japan & Chao-Chi Ho, Taiwan
Track: SCLC, Mesothelioma and Thymoma

14:30 -14:32 Welcome and Introduction
14:32 - 14:44 ES08.01: Chemotherapy for SCLC
Miyako Satouchi, Japan
14:44 - 14:56 ES08.02: Advances in immunotherapy in SCLC
Jie Wang, China
14:56 - 15:08 ES08.03: Carcinoid Tumor
Se-Hoon Lee, Republic of Korea
15:08 - 15:20 ES08.04: Radiation Therapy of Small Cell Lung Cancer
Yu Yang Soon, Singapore
15:20 - 15:30 Q&A Discussion

15:30 – 16:00 Networking Break
Exhibit Hall | Room 201+202 | 2F
Refreshments will be provided
**ES09 - Therapeutic Challenges in Locally Advanced NSCLC**

**Track: Locally Advanced NSCLC**

**16:00 – 16:02** Welcome and Introduction

**16:02 – 16:15** ES09.01: Treatment Options After Progression on Consolidation Immune Checkpoint Inhibition  
Qing Zhou, China

**16:15 – 16:28** ES09.02: Consolidation Immunotherapy for Driver Oncogene Positive Unresectable NSCLC  
Jii Bum Lee, Republic of Korea

**16:28 – 16:41** ES09.03: Respiratory Emergencies in Unresectable NSCLC  
Emily Stone, Australia

**16:41 – 16:54** ES09.04: Approach to Immune-Related Pneumonitis: Detection, Management and Re-Challenge  
Daichi Fujimoto, Japan

**16:54 – 17:00** Q&A Discussion

---

**Poster Viewing**

**Exhibit Hall | Room 201+202 | 2F**

17:00 - 18:30 Poster Tour 3

17:00 - 18:30 Poster Viewing Reception B

*For further details, please refer to the Poster Section, pages 24 - 26.*

**IS04 – Industry Symposium Sponsored by MSD K.K.**

**Plenary Hall | Room 203 | 2F**

**18:30 – 19:30** Chair: Takayasu Kurata, Japan

18:30 – 19:00 The Current Treatment and Future Perspective for Peri-operative NSCLC Treatment  
Yasuhiro Tsutani, Japan

19:00 – 19:30 Latest Achievement in Metastatic NSCLC  
Hiroaki Akamatsu, Japan

---

**ES10 - Palliative Care for Lung Cancer Patients**

**Breakout Room | Room 204 | 2F**

**16:00 – 17:00** Welcome and Introduction

**16:00 – 16:14** ES10.01: Integration of Oncology Care and Palliative Care  
David Hui, USA

**16:14 – 16:26** ES10.02: Latest Pain Management  
Yoshihisa Matsumoto, Japan

**16:26 – 16:38** ES10.03: Home-Based Palliative Care  
Chin-Yuan Shih, Taiwan

**16:38 - 16:50** ES10.04: Advance Care Planning  
Sun-Hyun Kim, Republic of Korea

**16:50 - 17:00** Q&A Discussion
SATURDAY | OCTOBER 29, 2022

Registration Desk Opening Hours: 07:00 – 13:15
Speaker Preview Center Opening Hours: 07:00 – 13:15

**IS05 – Industry Symposium Sponsored by Novartis Pharma K.K.: Update Lung Cancer with Rare Deliver Mutation from Basic Research to Clinical Practice**

Plenary Hall | Room 203 | 2F
Refreshments will be provided

- **07:30 – 08:30**  
  Chair: Koichi Goto, Japan
- **07:30 - 07:32**  
  Opening Remarks  
  Koichi Goto, Japan
- **07:32 - 07:57**  
  Current and Future Perspectives on Molecular Diagnostics and Targeted Therapies for Non-small Cell Lung Cancer  
  Shingo Matsumoto, Japan
- **07:57 - 08:22**  
  Current State of Targeted Therapy for Lung Cancer with Minor Driver Mutations and the Mechanism of Resistance  
  Seiji Yano, Japan
- **08:22 - 08:30**  
  Q&A Session

**PL03 – Evolving Landscape of Peri-Operative Therapy in NSCLC**

Plenary Hall | Room 203 | 2F

- **08:45 – 10:15**  
  Chairs: James Chih-Hsin Yang, Taiwan & Heather Wakelee, USA
- **08:45 – 08:47**  
  Welcome and Introduction
- **08:47 – 09:03**  
  PL03.01: Adjuvant Targeted Therapy  
  Masahiro Tsuboi, Japan
- **09:03 – 09:19**  
  PL03.02: Adjuvant Immunotherapy  
  Caicun Zhou, China
- **09:19 – 09:35**  
  PL03.03: Neoadjuvant Immunotherapy  
  CheckMate816  
  Tetsuya Mitsudomi, Japan
- **09:35 – 09:51**  
  PL03.05: Future Role of Surgeon in the Era of Immunotherapy  
  Paul Van Schil, Belgium
- **09:51 – 10:15**  
  Q&A Discussion

- **10:15 – 10:45**  
  Networking Break
  Exhibit Hall | Room 201+202 | 2F
  Refreshments will be provided

**ES11 - Therapeutic Progress of Mesothelioma and Thymic Neoplasms**

Plenary Hall | Room 203 | 2F

- **10:45 – 11:45**  
  Chairs: Steven Kao, Australia & Young Tae Kim, Republic of Korea
- **10:45 – 11:11**  
  Current State of Targeted Therapy for Lung Cancer with Minor Driver Mutations and the Mechanism of Resistance  
  Seiji Yano, Japan
- **11:11 – 11:45**  
  Q&A Discussion

**ES12 - Targeted Therapy**

Breakout Room | Room 204 | 2F

- **10:45 – 11:45**  
  Chairs: Dong Wan Kim, Republic of Korea & Misako Nagasaka, USA
- **10:45 – 11:02**  
  PL02.01: Targeting ALK as a Paradigm in Precision Oncology  
  Tony Mok, Hong Kong
- **11:02 – 11:17**  
  PL02.02: Emerging ROS1 and RET Inhibitors and their Combinations  
  Thananyan Baisamut, Thailand
- **11:17 – 11:32**  
  PL02.03: Drugging the Undruggable: International Collaboration on Targeting KRAS G12C  
  Bob Li, USA
- **11:32 – 11:45**  
  Q&A Discussion
IS06 – Industry Symposium Sponsored by Amgen K.K.: The Lung Cancer Treatment Landscape: Novel Targets and Treatment for Improved Patient Care
Breakout Room | Room 204 | 2F
Lunch will be provided

12:00 – 13:00 Chair: Tetsuya Mitsudomi, Japan
12:00 - 12:15 Biomarker Testing at Practice in East Asia
Yasushi Yatabe, Japan
12:15 - 12:30 KRAS G12C inhibitor Clinical Data
Bob Li, USA
12:30 - 13:00 Panel Discussion
Yasushi Yatabe, Japan, Bob Li, USA, Hidetoshi Hayashi, Japan

IS07 – Industry Symposium Sponsored by AstraZeneca K.K.: Adjuvant Therapy for EGFR Mutant Early-Stage NSCLC
Plenary Hall | Room 203 | 2F
Lunch will be provided

12:00 – 13:00 Chair: Hidehito Horinouchi, Japan
12:00 - 12:45 Current Status of Lung Cancer Perioperative Treatment
The Results of Clinical Trials which is Targeting EGFR Mutated NSCLC Patients, and Results of the ADAURA Study as a Recent Clinical Trial
Junko Tanizaki, Japan
12:45 - 13:00 Future Perspective for Perioperative Treatment Strategies by Prescribers

ES13 - Novel Targeted Therapies in Lung Cancer
Plenary Hall | Room 203 | 2F

13:15 – 14:15 Chairs: Tetsuya Mitsudomi, Japan & Kazuhiko Nakagawa, Japan
Track: Advanced/Metastatic NSCLC

13:15 – 13:17 Welcome and Introduction
13:17 – 13:30 ES13.01: ADC to TROP2 and CAECAM5
Byoung Chul Cho, Republic of Korea
13:30 – 13:43 ES13.02: Antibody Drug Conjugates to HER2 and HER3
Kazuhiko Nakagawa, Japan
James Chih-Hsin Yang, Taiwan
Noemí Reguart, Spain
14:09 – 14:15 Q&A Discussion

ES14 - Lineage Plasticity of Lung Cancer
Breakout Room | Room 204 | 2F

13:15 – 14:15 Chairs: Yasushi Yatabe, Japan & Chong-Jen Yu, Taiwan
Track: Translational Science, Basic Science and Pathology

13:15 – 13:17 Welcome and Introduction
Triparna Sen, USA
Yoon-La Choi, Republic of Korea
Teh-Ying Chou, Taiwan
Mitsuru Morimoto, Japan
14:05 – 14:15 Q&A Discussion
The 2023 Targeted Therapies of Lung Cancer Meeting will highlight information about ongoing clinical trials of the newest therapies for lung cancer including data on preclinical and early clinical trials.
Poster Sessions
### Poster Sessions

**THURSDAY | OCTOBER 27, 2022**

Exhibit Hall, Room 201+202, 2F

#### Poster Tour 1

18:00 - 19:00

**Discussant**  
Chong-Jen Yu, Taiwan will be facilitating a Poster Tour and discuss the following posters with the presenters at their posters in the Exhibit Hall.

*Delegates are invited to join the Poster Tour.*

<table>
<thead>
<tr>
<th>PPT01.01</th>
<th>Protein Changes during Immune-Related Adverse Events and Corticosteroid Treatment in Cancer Patients Receiving Immune Checkpoint Inhibitors</th>
<th>Hiroaki Kanemura, Japan</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPT01.02</td>
<td>Study on Tumor Immune Microenvironment of Pulmonary Lymphoepithelial Carcinoma Using Multiplex Immunohistochemical Staining</td>
<td>Wei-Hsun Hsu, Taiwan</td>
</tr>
</tbody>
</table>

#### Poster Tour 2

18:00 - 19:00

**Discussant**  
Sita Andarini, Indonesia will be facilitating a Poster Tour and discuss the following posters with the presenters at their posters in the Exhibit Hall.

*Delegates are invited to join the Poster Tour.*

<table>
<thead>
<tr>
<th>PPT02.01</th>
<th>Risk of Thromboembolism in NSCLC with Different Oncogenic Drivers, Including ROS1, ALK and EGFR Mutation</th>
<th>Hsin-Yi Wang, Taiwan</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPT02.02</td>
<td>Computer-Assisted Flagging of Never Smokers at High Risk of NSCLC in a Large US-Based HMO Using the LungFlag Model</td>
<td>Eran Netanel Choman, Israel</td>
</tr>
<tr>
<td>PPT02.03</td>
<td>Preoperative Localization Technique using Mixture of Indigo-Carmine and Lipiodol of Pulmonary Nodule via Transbronchial Approach</td>
<td>Soojin Lee, Republic of Korea</td>
</tr>
<tr>
<td>PPT02.04</td>
<td>Analysis of Pre-Analytic Factors Affecting the Success of Next-Generation Sequencing of Non-Small Cell Lung Cancer</td>
<td>Naoki Shiraishi, Japan</td>
</tr>
</tbody>
</table>

### Advanced/Metastatic NSCLC - Immunotherapy

18:00 - 19:00

**PP01.01**  
A Meta-Analysis for Treatment-Related Adverse Events of Combination Chemoimmunotherapy vs Chemotherapy in First-Line Treatment for NSCLC  
Kazuki Takada, Japan

**PP01.02**  
Central Nervous Systemic Efficacy of Immune Checkpoint Inhibitors and Concordance Between Intra/extra-cranial Response in Non-small Cell Lung Cancer Patients with Brain Metastasis  
Sora Kang, Republic of Korea

**PP01.03**  
Effectiveness of Adding Chemotherapy to ICI for First-Line Treatment of Advanced NSCLC with PD-L1 Score Around 50%: Regression Discontinuity Analysis  
Yuji Uehara, Japan

**PP01.04**  
Association of Thyroid Transcription Factor-1 with the Efficacy of Immune-Checkpoint Inhibitors in Patients with Advanced Lung Adenocarcinoma  
Kenji Nakahama, Japan

**PP01.06**  
Efficacy and Safety of Immune Checkpoint Inhibitors with Chemotherapy for Patients of Performance Status 2 with Advanced NSCLC  
Hirohisa Kano, Japan

**PP01.07**  
Prognostic Factor of TTF-1 Expression for Lung Adenocarcinoma Patients Received Chemotherapy Plus Immune Checkpoint Inhibitor  
Reina Goshono, Japan

**PP01.08**  
Analysis of the Effect of Mediastinal Lymph Node Dissection on the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer  
Yohei Kawaguchi, Japan

**PP01.09**  
Analyses of the Outcome of Immune Checkpoint Inhibitors for Postoperative Recurrent Disease in NSCLC  
Takafumi Hashimoto, Japan

**PP01.10**  
Long-Term Progression-Free Survival after Discontinuation of Immune Checkpoint Inhibitors  
Taiyo Nakamura, Japan

---

Conquering Thoracic Cancers Worldwide
Advanced/Metastatic NSCLC - Targeted Therapy

PP01.11  Success of Tepotinib Therapy in Overcoming Resistance to Osimertinib in a Patient with EGFR-Mutant Lung Adenocarcinoma With a Potential Acquired MET Exon 14 Skipping Mutation
Shinkichi Takamori, Japan

PP01.12  A Project to Investigate the Actual Status of Biomarker Testing in Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer: WJOG15421 L (REVEAL)
Toshihide Yokoyama, Japan

PP01.13  Efficacy and Intracranial Activity of Tepotinib in Japanese Patients with MET Exon 14 Skipping NSCLC (VISION)
Masahiro Morise, Japan

PP01.14  Tepotinib in Asian Patients with Advanced NSCLC with MET Exon 14 (METex14) Skipping
Terufumi Kato, Japan

PP01.16  Resistance Mechanisms to Osimertinib in Advanced EGFR-Mutated NSCLC: An Update from a Single Institution Prospective Cohort Study
Bin-Chi Liao, Taiwan

PP01.17  Phase 1/2a Study Evaluating Alectinib Pharmacokinetics and Efficacy in Hispanic Population with Advanced ALK-rearranged Non-small Cell Lung Cancer
Oscar Arrieta, Mexico

PP01.18  Clinical Outcomes for EGFR and HER2 exon 20 Insertion-Mutated Advanced Lung Cancer
Kelly Li, Canada

Sik-Kwan Chan, Hong Kong

PP01.20  Prevalence of Central Nervous System Metastasis in EGFR Mutated Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study
Archara Supavavej, Thailand

PP01.21  Clinical Characteristics and Real-World Progression-Free Survival of Patients with EGFR Mutation-Positive Adenocarcinoma Lung Cancer Treated with EGFR as the First Line: A Retrospective Cohort Study from Indonesia
Noni Novisari Soeroso, Indonesia

PP01.22  The Detection Rate of EGFR Gene Mutations in the Cobas EGFR Mutation Test and the Oncomine Dx Target Test Multi-CDx System in Our Hospital
Masahide Ota, Japan

PP01.23  Differences in First Generation EGFR-TKI Responses in Advanced Stage Lung Adenocarcinoma with EGFR Mutations
Uun Unaedi, Indonesia

PP01.24  Survival Difference of EGFR Exon 19 Deletion and Exon 21 Mutation in Asian Patients with Advanced Non-small Cell Lung Cancer
Dawn Lynn Guardiario, Philippines

Translational Science, Pathology and Basic Science

PP01.26  Impact of AXL Expression on the Efficacy of Osimertinib in Untreated EGFR-Mutated NSCLC
Tadaaki Yamada, Japan

PP01.27  Exploration of Secondary Resistant Mutations Against Mobocertinib - in Vitro Study with Various EGFR Exon 20 Insertion Models
Akira Hamada, Japan

PP01.28  The Utility of the Anti-CKAP4 Monoclonal Antibody in DKK1-CKAP4 Signal-Activated Lung Cancer
Akihiro Nagoya, Japan

PP01.30  Mir-503 Pleiotropically Regulates Epithelial-Mesenchymal Transition and Targets PTK7 to Control Lung Cancer Metastasis
Tzu-Hsiu Tsai, Taiwan

PP01.31  Programmed Death-Ligand 1 Promotes Chemotaxis in EGFR-Mutant Non-Small Cell Lung Cancer through Regulating Cytokine Expression
Chia-Chi Hsu, Taiwan

PP01.32  Activation of EIF2 Signaling and HIF-1α Signaling as Possible Mechanisms of NSCLC Tumor Cell Proliferation Through Induction of Autophagy
Ferdinand Mira, Philippines

PP01.33  Clinical and Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors
Shang-Gin Wu, Taiwan

PP01.34  ACTN4 is Related to the Migration and Proliferation of Thymic Cancer Through β-catenin Pathway
Hideki Nagata, Japan

PP01.35  Dysregulation of Lipid Metabolism Leads to Resistance of Lung Cancer Stem Cells to Reactive Oxygen Species-Induced Cell Death
Han-shui Hsu, Taiwan

PP01.37  Dynamic Alteration of Peripheral Immune Cells in Patients with NSCLC Received Anti-PD-1/PD-L1 Therapy and Clinical Efficacy
Naruo Yoshimura, Japan

PP01.38  Cyclooxygenase-2 Expression Level in Primary Tumors is Associated with Vasculogenic Mimicry Formation and Survival in T1 Lung Adenocarcinoma
Ming-Wei Kao, Taiwan
PP01.39  Expression of Cluster Differentiation 109 Promotes Tumorigenesis and Is Associated with an Adaptive Immune Resistance in Lung Adenocarcinoma
Chengwei Lin, Taiwan

PP01.41  Immunohistochemistry Techniques to Differentiate Adenocarcinoma or Squamous Cell Lung Cancer
Linda Masniari, Indonesia

PP01.42  Diagnosis of MET Gene Alterations in Advanced NSCLC with Next Generation Sequencing
Nguyen Son Lam, Vietnam
Poster Sessions

FRIDAY | OCTOBER 28, 2022
Exhibit Hall, Room 201+202, 2F

**Poster Tour 3**
17:00 - 18:30

**Discussant**
Keunchil Park, Republic of Korea will be facilitating a Poster Tour and discuss the following posters with the presenters at their posters in the Exhibit Hall.
Delegates are invited to join the Poster Tour.

**PPT03.01**
Phase II Study of S-1 and Cisplatin with Concurrent Thoracic Radiotherapy Followed by Durvalumab for Unresectable, Locally Advanced Non-Small-Cell Lung Cancer in Japan (SAMURAI Study)
Kazuhiko Shibata, Japan

**PPT03.03**
Prognosis and Efficacy of Adjuvant Therapy in Post-Surgical NSCLC Patients with WES Based Genetic Profiling
Akiko Tateishi, Japan

**PPT03.04**
AI-based Quantitative CT Analysis for Prediction of Radiation Pneumonitis after Stereotactic Body Radiotherapy for the Lung
Masahiro Yoneyama, Japan

**PPT03.05**
Atezolizumab + Bevacizumab vs Atezolizumab Alone as First Line Treatment of Patients with EGFR Mutated NSCLC: Subgroup Analysis of a Randomized, Phase II Study: AteBev-CS
Toshiyuki Kozuki, Japan

**PPT03.06**
The Case Fatality Rate of COVID-19 Infection and Effect on Systemic Treatment of COVID-19 Infection in Non-Small Cell Lung Cancer
Yeji Jung, Republic of Korea

**Poster Sessions**
With Presenters Available for Questions
17:00 - 18:30

**Diagnosis, Imaging and Bronchoscopy**

**PP02.01**
Role of Bronchoscopy for Lung Cancer Diagnosis in Elderly Patients
Hye-rin Kang, Republic of Korea

**PP02.02**
Respiratory Sarcopenia Predicts Postoperative Outcomes in Patients with Non-Small Cell Lung Cancer
Yoshifumi Hirata, Japan

**PP02.03**
Shared Presurgical Understanding for Lung Cancer in Patient’s Acquaintances Using CT-Derived 3D Virtual Explanation Module
Kwon Joong Na, Republic of Korea

**PP02.04**
Multiple Non-Small Cell Lung Cancers Including One Tumor with EGFR Mutation and Another Without That
Taisuke Matsubara, Japan

**PP02.05**
Postoperative Pleuroparenchymal Fibroelastosis (PPFE) like Ipsilateral Upper Lung Field Pulmonary Fibrosis, Differentiation from the Lung Cancer Recurrence
Takao Nakanishi, Japan

**PP02.06**
Primary Pure Signet-Ring Cell Carcinoma of Lung with ALK Rearrangement – Case Report
Akira Okimura, Japan

**PP02.07**
Pilot Study for Early Diagnosis of Lung Cancer in a Public Hospital in Northeast Brazil
Carlos De Araújo, Brazil

**PP02.08**
The Usefulness of Liquid Biopsy When Biopsy Not Feasible in a Patient of EGFR Positive Non-Small Cell Lung Cancer (NSCLC), a Case Report
Yeongha Ryu, Republic of Korea

**PP02.09**
A Long Term Follow-Up of Papillary Thyroid Carcinoma Arising in Mature Cystic Mediastinal Teratoma
Ananda Febriani Aulia, Indonesia

**Early Stage NSCLC**

**PP02.10**
Surgery Perioperative Electrolyte Levels and Postoperative Atrial Fibrillation Following Robotic-Assisted Pulmonary Lobectomy
Lauren Ladehoff, USA

**PP02.11**
Effect of PM2.5 on Tumor Recurrence, Mortality, and Postoperative Complications in Resectable Non-Small Cell Lung Carcinoma: A Retrospective Cohort Study
Sophon Siwachat, Thailand

**PP02.12**
A Trans-omics Assessment of Gene-gene Interaction in Early Stage NSCLC
Li Su, USA

**PP02.13**
Comparison Between Lobectomy and Proton Therapy for Confirmed Stage I Lung Cancer
Tadashi Sakane, Japan

**PP02.14**
Prognostic Impact of Ground Glass Opacity Component and Consolidation Size in Clinical Stage IA Lung Adenocarcinoma After Sublobar Resection: A Quantitative Analysis
Jae Kwang Yun, Republic of Korea

**PP02.15**
Long-Term Results of Transbronchial ICG Administration in Limited Surgery for Early Stage Lung Cancer
Yasu Seke, Japan
| PP02.16 | Correlation of SUVmax of Primary Lung Tumor and Occult Lymph Node Metastases in Clinical Stage I Lung Adenocarcinoma | Kenichi Suda, Japan |
| PP02.17 | Challenges of the Eighth Edition of the American Joint Committee on Cancer Staging System for Pathologists Focusing on Early-Stage Lung Adenocarcinoma | Shiu-feng Huang, Taiwan |
| PP02.18 | Effects of Insurance Type and Distance from the Cancer Center on Outcomes after Robotic-Assisted Pulmonary Lobectomy | Allison Dumitruiu Carcoana, USA |
| PP02.19 | Impact of Preoperative Cardiovascular Comorbidities on Perioperative Outcomes After Robotic-Assisted Pulmonary Lobectomy | Jenna Marek, USA |
| PP02.20 | Postoperative Atrial Fibrillation Propensity After Robotic-Assisted Pulmonary Lobectomy by Number of Segments | Cole Fiedler, USA |
| PP02.21 | Impact of the COVID-19 Pandemic on Perioperative Outcomes after Robotic-Assisted Pulmonary Lobectomy | William Doyle, USA |
| PP02.22 | Effect of Gender on Incidences of Perioperative Complications after Robotic-Assisted Video-Thoracoscopic Pulmonary Lobectomy | Kristie Labib, USA |
| PP02.23 | Effects of Perioperative Potassium Levels on Incidence of Postoperative Complications Following Robotic-Assisted Pulmonary Lobectomy | Lauren Ladehoff, USA |
| PP02.24 | Adenocarcinoma In Situ Manifesting as a Part Solid Nodule with High CTR: Radiologic and Pathologic Characteristics | Emi Hagui, Japan |
| PP02.25 | Fibroblast Activation Protein Expression in the Alveolar Structures of Patients with Lung Adenocarcinomas | Toru Kimura, Japan |
| PP02.26 | Selection of Surgery Focusing on Lymph Node Dissection: Robot-Assisted Surgery or Single Port Thoracoscopic Surgery? | Yuki Yagi, Japan |
| PP02.27 | Treatment Outcomes of Surgery and SBRT for Early Lung Cancer | Chi Young Kim, Republic of Korea |

**Locally Advanced NSCLC**

| PP02.28 | Analysis of PD-L1 Negative Subgroups in Real World Survey (CRIMSON) of Definitive Chemoradiotherapy in Locally Advanced NSCLC | Hayato Kawachi, Japan |
| PP02.29 | Dynamic Change of Immune Repertoire Profiling in Stage III Non-Small Cell Lung Cancer (NSCLC) Patients During Consolidation Treatment With Immunotherapy | Dulyathat Anantaya, Thailand |
| PP02.30 | Normalization of Tumor Marker Value Predicts Better Prognosis in Patients with Unresectable Stage III NSCLC | Momoko Morishita, Japan |
| PP02.31 | MMP3, Fractalkine and MIF are Associated with Clinical Outcomes in Locally Advanced NSCLC Treated with Chemoradiotherapy and Durvalumab | Yoshiro Nakahara, Japan |
| PP02.32 | A Phase II Trial of Biweekly Carboplatin and Nab-Paclitaxel with Concurrent Radiotherapy for Patients with Locally Advanced Unresectable Stage III Non-Small Cell Lung Cancer: Long Follow up Survival Data | Hisashi Tanaka, Japan |
| PP02.33 | Peripheral Blood Markers Correlate with Pathological Complete Response and Prognosis in Resectable NSCLC Patients Treated with Neoadjuvant Chemoimmunotherapy | Yan Hu, China |
| PP02.34 | Feasibility of Hypo-Fractionated Radiotherapy (55 Gy/20 Fractions) in NACT Unresponsive and Co-Morbid Patients of NSCLC | Anupam Datta, India |
| PP02.35 | Locally Advanced Non-Small Cell Lung Carcinoma as a Non-Mucinous Adenocarcinoma in a 15-Year-Old Child: A Rare Presentation | Vijay Kumar, India |
| PP02.36 | Pulmonary Carcinosarcoma: A Report Case from Vietnam | Linh Le Tu, Vietnam |

**Palliative and Supportive Care**

| PP02.37 | Affective Quality of Life and Burden of Lung Symptoms in Patients with Suspected Lung Cancer: A Prospective Longitudinal Study | Narongwit Nakwan, Thailand |
| PP02.38 | The Great Survival Benefit from Ma Recipe Therapeutics for Patients with Advanced Lung Cancer: A Retrospective Study | Jiangnan Feng, China |
| PP02.39 | Hippocampal Avoidance Whole Brain Radiotherapy with Simultaneous Integrated Boost – An Alternative to Stereotactic Radiosurgery? | Anil Tibdewal, India |
## Risk Reduction, Early Detection, Epidemiology and Tobacco Control

**PP02.40** Electronic Cigarettes Use and ‘Dual-Use’ Among the Youth in 75 Countries - Estimates from Global Youth Tobacco Surveys (2014-2019)  
Chandrashekhar Sreeramareddy, Malaysia

**PP02.41** Role of Preoperative Inhalation Therapy for Lung Cancer Patients with Chronic Obstructive Pulmonary Disease  
Yasushi Shintani, Japan

**PP02.42** Clinical Significance of the TTR / RBP Ratio in Patients Undergoing Surgery for Lung Cancer  
Jun Suzuki, Japan

**PP02.43** Impact of a Multidisciplinary Team Conference on Non-Small Cell Lung Cancer Care: Time Barriers and Long-Term Outcomes  
Apichat Tantraworasin, Thailand

**PP02.44** Relationship Between Worsening Postoperative Dyspnea and Preoperative Respiratory Function  
Takuya Ohashi, Japan

**PP02.45** An Investigation on Inflammatory and Oncological Biomarkers in Lung Cancer Diagnosis: A Data-Driven Approach  
Mohammad Tanvir Ahamed, Sweden

**PP02.46** Sublobar Resection Might Be Effective Option for Lung Cancer Patients on Dialysis  
Hiroki Matsumoto, Japan

## SCLC, Mesothelioma, Thymoma

**PP02.47** Two Cases of Sarcomatoid Mesothelioma from Mesothelioma in Situ  
Naoe Jimbo, Japan

**PP02.48** Semi-Rigid Thoracoscopy using Small Forceps; a Promising Diagnostic Method for Malignant Pleural Mesothelioma  
Yun Seok Kim, Republic of Korea

**PP02.49** Paraneoplastic Neurological Syndrome in Small Cell Lung Cancer  
Takayo Ota, Japan

**PP02.50** A Real-World Study on the Efficacy and Safety of PD-L1 inhibitor Plus Platinum-Etoposide Chemotherapy in Patients with Extensive Stage SCLC: A Prospective Observational Study  
Kenji Morimoto, Japan

**PP02.51** Life Expectancy after Discontinuation of Chemotherapy in Patients with Small Cell Lung Cancer  
Kazushi Yoshida, Japan

**PP02.52** Clinical Profile, Prognostic Factors, and Treatment Outcomes in Patients of Thymoma: A Decade of Experience from a Single Centre  
Divya Khosla, India

**PP02.53** Neuro-Cognitive Effect of WB-PCI in LS-SCLC  
Suryakanta Acharya, India

**PP02.54** Experience in the Treatment of Patients with Advanced Thymic Cancer  
Yuki Akazawa, Japan

---

## VIRTUAL POSTERS ONLY

**PV01.01** Individualized Prediction of Survival Benefit from Postoperative Radiotherapy for Patients with Malignant Pleural Mesothelioma  
Yang Wo, China

**PV01.02** Experience of Cyto-reductive Surgery and Intra-Operation Adjuvant Therapy for Malignant Pleural Mesothelioma at a Single Center in Taiwan  
Yei San Hsieh, Taiwan

**PV01.03** A Phase I Trial of the HER2 TKI, BI 1810631, in Patients with Advanced Solid Tumors with HER2 Aberrations  
Noboru Yamamoto, Japan

**PV01.04** Clinical Trials During Covid Pandemic - The Show Must Go On  
Mansi Sharma, India

**PV01.05** Efficacy of Immunotherapy in Second-Line Treatment of KRAS Mutated Patients with Non-Small Cell Lung Cancer - Data from Daily Practice  
Magdalena Knetki-Wróblewska, Poland

**PV01.06** The Value of Next-Generation Sequencing in the Differential Diagnosis of Mediastinal Tumor (Case Report)  
Magdalena Knetki-Wróblewska, Poland

**PV01.07** Predictors of Psychological Distress in Informal Caregivers of Patients after Surgical Treatment of Early-Stage Lung Cancer  
Song Zhu, China

**PV01.08** Liquid Biopsy-Based Fragmentomic Assay for Malignancy Classification of Radiographically Highly Suspicious Lung Nodules  
Rong Yin, China

**PV01.09** Electronic Cigarettes Use and ‘Dual-Use’ Among the Youth in 75 Countries- Estimates from Global Youth Tobacco Surveys (2014-2019)  
Chandrashekhar Sreeramareddy, Malaysia

**PV01.10** Modulating EGFR TKI Resistance by Dosage and Timing  
Jo Monsen, Norway

**PV01.11** Unique Molecular Properties of East Asian EGFR-Mutant Non-Small Cell Lung Cancer Patients at Early and Advanced Stages: K-MASTER Project  
Yoon Ji Choi, Republic of Korea

**PV01.12** Comparison of Adjuvant Osimertinib, 1st TKIs, Chemo-TKI, Immunotherapy and Chemotherapy for Resected EGFR-Mutant NSCLC – an Updated Network Meta-Analysis of 3300 Patients  
Guang-Ling Jie, China
Join us for WCLC 2023 in Singapore!
Abstract Submissions will open in January 2023.
Showcase your research and contribute to discussions that will shape the future of treatments in lung cancer and thoracic malignancies.

#WCLC23
WLCL2023.IASLC.org
Education Awards
Education Awards

Congratulations to the following ACLC 2022 Education Award Winners!
Award Winners will be presented with their awards during Plenary 2 on Friday, October 28 from 08:45 – 10:15.

**Wonyoung Jung, Republic of Korea**
OA02.05: Fear of Cancer Recurrence and its Predictors among Patients with Non-Small Cell Lung Cancer (NSCLC)
- **OA02 - Oral Abstract Session 2, Friday, October 28** 13:15 – 14:30

**Alvaro Quintanal-Villalonga, USA**
OA02.03: AKT Pathway as a Therapeutic Target to Constrain Lineage Plasticity Leading to Histological Transdifferentiation
- **OA02 - Oral Abstract Session 2, Friday, October 28** 13:15 – 14:30

**Prerna Gautam, India**
OA01.02: Operational Management Challenges in Continuing Lung Cancer Screening during COVID-19 Pandemic
- **OA01 - Oral Abstract Session 1, Thursday, October 27** 17:00 – 18:00

**Tadashi Sakane, Japan**
PP02.13: Comparison Between Lobectomy and Proton Therapy for Confirmed Stage I Lung Cancer
- **Poster Viewing Reception B, Friday, October 28** 17:00 – 18:30

**Sora Kang, Republic of Korea**
PP01.02: Central Nervous Systemic Efficacy of Immune Checkpoint Inhibitors and Concordance Between Intra/extracranial Response in Non-small Cell Lung Cancer Patients with Brain Metastasis
- **Poster Viewing Reception A, Thursday, October 27** 18:00 – 19:00

**Yang Wo, China**
PV01.01: Individualized Prediction of Survival Benefit from Postoperative Radiotherapy for Patients with Malignant Pleural Mesothelioma
- **Virtual Poster**

**Guang-Ling Jie, China**
PPT03.02: Comparison of Adjuvant Osimertinib, 1st TKIs, Chemo-TKI, Immunotherapy and Chemotherapy for Resected EGFR-Mutant NSCLC – an Updated Network Meta-Analysis of 3300 Patients
- **Poster Tour 3, Friday, October 28** 17:00 – 18:30
The *Journal of Thoracic Oncology (JTO)*, the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of thoracic malignancies. JTO emphasizes a multidisciplinary approach, and includes original research (clinical trials, and translational or basic research), reviews, and opinion pieces. The audience consists of epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonary specialists, radiologists, pathologists, and research scientists with a special interest in thoracic oncology.
Industry Supporters & Exhibitors
The IASLC 2022 Asia Conference on Lung Cancer would like to thank the following companies for their support:

**GOLD LEVEL SUPPORT:**

![Elevation Oncology](image)

**EXHIBITORS:**

![ACT Genomics](image)

![Japan Lung Cancer Society](image)

**INDUSTRY SYMPOSIA SPONSORS:**

![Amgen](image)

![AstraZeneca](image)

![Merck](image)

![MSD](image)

![Novartis](image)

![PER](image)
General Information

HEALTH & SAFETY MEASURES
ACLC 2022 will be hosted as an in-person meeting in Nara, Japan at the Nara Prefectural Convention Center. The health and safety of all our stakeholders are of the utmost importance. Although we are excited to welcome you to Nara, all necessary precautions will be taken to ensure a safe environment throughout the Conference.

The following measures will be put in place and enforced on-site to achieve this commitment (applicable to all staff, delegates, exhibitors, sponsors, and guests):

MASKS AND FACE COVERINGS
In accordance with the Japanese Ministry of Health, Labor and Welfare, the wearing of masks is mandatory at the Nara Convention Center and will be enforced.

By registering to attend, you agree that:
• You will not attend if you have any COVID-19 symptoms
• If during your attendance you develop any COVID-19 symptoms, you will immediately:
  - Self-isolate;
  - Comply with all local/national government restrictions; and
  - Inform the ACLC 2022 Conference Secretariat by email (aclc022-registration@icsevents.com).

IASLC and their suppliers will in their best effort, provide a safe environment to meet. It is expected that all participants will follow the measures to help reduce the risk.

Please note: There will be no on-site testing facility available at ACLC 2022.

ACCESS/SECURITY
Attendees are requested to wear their name badges at all times in order to participate in the Scientific Sessions and Exhibition. A 50 USD fee applies for any name badge reprints due to lost name badges.

OPENING HOURS

Registration Desk
Lobby, 2F

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, October 27</td>
<td>09:30 – 18:00</td>
</tr>
<tr>
<td>Friday, October 28</td>
<td>08:00 – 16:00</td>
</tr>
<tr>
<td>Saturday, October 29</td>
<td>07:00 – 13:15</td>
</tr>
</tbody>
</table>

Networking Lunch & Breaks

<table>
<thead>
<tr>
<th>Day</th>
<th>Lunch Break: 12:00 – 12:30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, October 27</td>
<td>Plenary Hall</td>
</tr>
<tr>
<td>PM Break: 15:00 – 15:45</td>
<td></td>
</tr>
<tr>
<td>Exhibit Hall</td>
<td>Room 201+202</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Day</th>
<th>AM Break: 10:15 – 10:45</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, October 28</td>
<td>Exhibit Hall</td>
</tr>
<tr>
<td>PM Break: 15:30 – 16:00</td>
<td></td>
</tr>
<tr>
<td>Exhibit Hall</td>
<td>Room 201+202</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Day</th>
<th>AM Break: 10:15 – 10:45</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, October 29</td>
<td>Exhibit Hall</td>
</tr>
</tbody>
</table>

Exhibit Hours

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, October 27</td>
<td>12:00 – 19:00</td>
</tr>
<tr>
<td>Friday, October 28</td>
<td>10:00 – 18:30</td>
</tr>
<tr>
<td>Saturday, October 29</td>
<td>10:00 – 13:50</td>
</tr>
</tbody>
</table>

Prayer / Mothers Room

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, October 27</td>
<td>09:30 – 20:00</td>
</tr>
<tr>
<td>Friday, October 28</td>
<td>08:00 – 19:30</td>
</tr>
<tr>
<td>Saturday, October 29</td>
<td>07:00 – 14:30</td>
</tr>
</tbody>
</table>

Speaker Preview Center

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, October 27</td>
<td>09:30 – 17:00</td>
</tr>
<tr>
<td>Friday, October 28</td>
<td>08:00 – 16:00</td>
</tr>
<tr>
<td>Saturday, October 29</td>
<td>07:00 – 13:15</td>
</tr>
</tbody>
</table>

Poster Viewing

Exhibit Hall, Room 201+202, 2F

Posters for Session 1
- Advanced/Metastatic NSCLC – Immunotherapy
- Advanced/Metastatic NSCLC - Targeted Therapy
- Translational Science, Pathology and Basic Science

Posters for Session 2
- Diagnosis, Imaging and Bronchoscopy
- Early Stage NSCLC
- Locally Advanced NSCLC
- Palliative and Supportive Care
General Information

ACCESS VIRTUAL RECORDINGS
(VIRTUAL PLATFORM)
All Scientific sessions will be audio recorded and made available on the Virtual Platform within 24 hours. The Virtual Platform also includes presentations slides, abstracts, and electronic versions of most posters. Log-in details including passwords were sent to your registered email in the Final Registration Confirmation email.

If you need assistance, please contact:
ACLC2022-Registration@icesevents.com.

Access to the ACLC 2022 Virtual Platform at:
https://aclc22-iaslc.junolive.co/

CERTIFICATE OF ATTENDANCE
Delegates can download their ‘Certificate of Attendance’ after completing the online Conference evaluation form sent to you by email at the conclusion of the Conference.

The IASLC ACLC 2022 is not accredited and does not provide CME credits or certifications for attending sessions.

WIFI
Wi-Fi will be provided in the meeting space area.
Network Name: meeting-room200
Password: naracc01

LOST & FOUND
Lost and found items should be returned / claimed at the Registration Desk.
Immunohistochemistry is an extremely valuable and powerful technique for pathologic diagnosis.

Published by the IASLC and its Pathology Committee, the IHC Atlas takes a comprehensive look at diagnostic IHC and its role in thoracic pathology. The IHC Atlas is a useful reference for anyone interested in thoracic tumor diagnostics, from basic researchers to practicing oncologists. All pathologists should have access to these best practices. The Atlas is available in multiple languages.

Scan the QR code to order your copy today!

Coming Soon!
IASLC Atlas on Molecular Biomarker Testing for Targeted Therapy
Available in February 2023
JTO Clinical and Research Reports is the official open access journal of the International Association for the Study of Lung Cancer. It aims to complement the Journal of Thoracic Oncology by offering authors a gold open access publication option and publishing of the following article types in particular:

- Phase I trials
- Well-performed single-arm phase II trials
- Small to moderate-sized randomized phase II trials
- Subset analyses of published trials
- Impactful retrospective studies
- Database and registry analysis
- Large institutional series
- High-quality case reports
- Region-specific clinical trials
- Subspecialty specific thoracic oncology studies
- Selected high-quality meeting reports

Now indexed in PubMed Central!
IASLC 2023
MEETINGS SCHEDULE

IASLC 2023 Latin America Conference on Lung Cancer
January 25-27, 2023
Montevideo, Uruguay
#LALCA23

IASLC 2023 Targeted Therapies of Lung Cancer Meeting
February 22-25, 2023
Santa Monica, California, USA
#TTLC23

IASLC 2023 World Conference on Lung Cancer
September 9-12, 2023
Singapore
#WCLC23

IASLC.org/Meetings-Webinars

Scan the QR code for information on upcoming meetings and webinars.

CONNECT WITH US
@IASLC
facebook.com/IASLC
@iaslungcancer
linkedin.com/IASLC
IASLC

* Location and dates subject to change
Join the IASLC Today!

Scan the QR code & enter ACLCNewMember2022 to receive half off membership dues for one year.